VV169 / Vyriad - LARVOL DELTA

Vyriad…announced the closing of the $25M final tranche to its Series B financing, bringing the total Series B round to $85M (Businesswire) - "This additional funding supports the imminent first-in-human testing of VV169, Vyriad’s in vivo CAR-T candidate, in patients with relapsed or treatment-refractory multiple myeloma....'We are optimistic about the potential of our wholly owned in vivo CAR T therapy, which will enter the clinic in 2026'."

Financing • First-in-human • New trial • Multiple Myeloma

Lead in vivo CAR T candidate VV169 (Businesswire) - "100% of mice treated with a single intravenous injection of therapy cleared OPM-2 tumors completely within 28 days. This response held true for all dose levels, including the lowest dose tested. The mice remained tumor-free 84 days post-treatment and successfully resisted tumor re-challenge; The treatment was well tolerated. Analysis of cytokines confirmed the absence of a severe cytokine storm. While IFNγ was elevated during T-cell expansion, inflammatory markers, such as IL-6, TNFα and GM-CSF, were barely detectable....Vyriad is continuing preclinical work for the development of VV169 and plans to begin a clinical trial in the U.S. in 2026."

New trial • Preclinical • Multiple Myeloma